Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

Jonklaas, J, Bianco, AC, Cappola, AR, Celi, FS, Fliers, E, Heuer, H, McAninch, EA, Moeller, LC, Nygaard, B, Sawka, AM, Watt, T & Dayan, CM 2021, 'Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document', Thyroid, bind 31, nr. 2, s. 156-182. https://doi.org/10.1089/thy.2020.0720

APA

Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., Watt, T., & Dayan, C. M. (2021). Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid, 31(2), 156-182. https://doi.org/10.1089/thy.2020.0720

CBE

Jonklaas J, Bianco AC, Cappola AR, Celi FS, Fliers E, Heuer H, McAninch EA, Moeller LC, Nygaard B, Sawka AM, Watt T, Dayan CM. 2021. Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid. 31(2):156-182. https://doi.org/10.1089/thy.2020.0720

MLA

Vancouver

Author

Jonklaas, Jacqueline ; Bianco, Antonio C. ; Cappola, Anne R. ; Celi, Francesco S. ; Fliers, Eric ; Heuer, Heike ; McAninch, Elizabeth A. ; Moeller, Lars C. ; Nygaard, Birte ; Sawka, Anna M. ; Watt, Torquil ; Dayan, Colin M. / Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism : A Consensus Document. I: Thyroid. 2021 ; Bind 31, Nr. 2. s. 156-182.

Bibtex

@article{1d51a4c9e1df4825a2b86d3258b51386,
title = "Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document",
abstract = "Background: Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Methods: The American Thyroid Association (ATA), British Thyroid Association (BTA), and European Thyroid Association (ETA) held a joint conference on November 3, 2019 (live-streamed between Chicago and London) to review new basic science and clinical evidence regarding combination therapy with presentations and input from 12 content experts. After the presentations, the material was synthesized and used to develop Summary Statements of the current state of knowledge. After review and revision of the material and Summary Statements, there was agreement that there was equipoise for a new clinical trial of combination therapy. Consensus Statements encapsulating the implications of the material discussed with respect to the design of future clinical trials of LT4/LT3 combination therapy were generated. Authors voted upon the Consensus Statements. Iterative changes were made in several rounds of voting and after comments from ATA/BTA/ETA members. Results: Of 34 Consensus Statements available for voting, 28 received at least 75% agreement, with 13 receiving 100% agreement. Those with 100% agreement included studies being powered to study the effect of deiodinase and thyroid hormone transporter polymorphisms on study outcomes, inclusion of patients dissatisfied with their current therapy and requiring at least 1.2 μg/kg of LT4 daily, use of twice daily LT3 or preferably a slow-release preparation if available, use of patient-reported outcomes as a primary outcome (measured by a tool with both relevant content validity and responsiveness) and patient preference as a secondary outcome, and utilization of a randomized placebo-controlled adequately powered double-blinded parallel design. The remaining statements are presented as potential additional considerations. Discussion: This article summarizes the areas discussed and presents Consensus Statements to guide development of future clinical trials of LT4/LT3 combination therapy. The results of such redesigned trials are expected to be of benefit to patients and of value to inform future thyroid hormone replacement clinical practice guidelines treatment recommendations.",
keywords = "Consensus, Drug Combinations, Evidence-Based Medicine, Humans, Hypothyroidism/blood, Thyroxine/adverse effects, Treatment Outcome, Triiodothyronine/adverse effects, clinical trial, patient-reported outcomes, hypothyroidism, levothyroxine, combination therapy, liothyronine",
author = "Jacqueline Jonklaas and Bianco, {Antonio C.} and Cappola, {Anne R.} and Celi, {Francesco S.} and Eric Fliers and Heike Heuer and McAninch, {Elizabeth A.} and Moeller, {Lars C.} and Birte Nygaard and Sawka, {Anna M.} and Torquil Watt and Dayan, {Colin M.}",
note = "Funding Information: The authors thank the ATA, BTA, and ETA for supporting and sponsoring the symposium on which this document is based. We thank the patient participants (formal speakers and audience members) who shared their perspectives in the symposium. Unrelated to this effort, L.C.M., and H.H., were supported by Deutsche Forschungsgemeinschaft within CRC/TR 296 LocoTact; F.S.C., was supported by the NIHNIDDK grant 1 R21 DK122310-01; J.J., was supported by NIDCR grant 5R01DE025822-05. Funding Information: The authors thank the ATA, BTA, and ETA for supporting and sponsoring the symposium on which this document is based. We thank the patient participants (formal speakers and audience members) who shared their perspectives in the symposium. Unrelated to this effort, L.C.M., and H.H., were supported by Deutsche Forschungsgemeinschaft within CRC/TR 296 LocoTact; F.S.C., was supported by the NIH-NIDDK grant 1 R21 DK122310-01; J.J., was supported by NIDCR grant 5R01DE025822-05. Publisher Copyright: {\textcopyright} Copyright 2021, Mary Ann Liebert, Inc., publishers American Thyroid Association European Thyroid Association (Published by S. Karger AG, Basel) 2021. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = feb,
day = "1",
doi = "10.1089/thy.2020.0720",
language = "English",
volume = "31",
pages = "156--182",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann/Liebert, Inc. Publishers",
number = "2",

}

RIS

TY - JOUR

T1 - Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism

T2 - A Consensus Document

AU - Jonklaas, Jacqueline

AU - Bianco, Antonio C.

AU - Cappola, Anne R.

AU - Celi, Francesco S.

AU - Fliers, Eric

AU - Heuer, Heike

AU - McAninch, Elizabeth A.

AU - Moeller, Lars C.

AU - Nygaard, Birte

AU - Sawka, Anna M.

AU - Watt, Torquil

AU - Dayan, Colin M.

N1 - Funding Information: The authors thank the ATA, BTA, and ETA for supporting and sponsoring the symposium on which this document is based. We thank the patient participants (formal speakers and audience members) who shared their perspectives in the symposium. Unrelated to this effort, L.C.M., and H.H., were supported by Deutsche Forschungsgemeinschaft within CRC/TR 296 LocoTact; F.S.C., was supported by the NIHNIDDK grant 1 R21 DK122310-01; J.J., was supported by NIDCR grant 5R01DE025822-05. Funding Information: The authors thank the ATA, BTA, and ETA for supporting and sponsoring the symposium on which this document is based. We thank the patient participants (formal speakers and audience members) who shared their perspectives in the symposium. Unrelated to this effort, L.C.M., and H.H., were supported by Deutsche Forschungsgemeinschaft within CRC/TR 296 LocoTact; F.S.C., was supported by the NIH-NIDDK grant 1 R21 DK122310-01; J.J., was supported by NIDCR grant 5R01DE025822-05. Publisher Copyright: © Copyright 2021, Mary Ann Liebert, Inc., publishers American Thyroid Association European Thyroid Association (Published by S. Karger AG, Basel) 2021. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/2/1

Y1 - 2021/2/1

N2 - Background: Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Methods: The American Thyroid Association (ATA), British Thyroid Association (BTA), and European Thyroid Association (ETA) held a joint conference on November 3, 2019 (live-streamed between Chicago and London) to review new basic science and clinical evidence regarding combination therapy with presentations and input from 12 content experts. After the presentations, the material was synthesized and used to develop Summary Statements of the current state of knowledge. After review and revision of the material and Summary Statements, there was agreement that there was equipoise for a new clinical trial of combination therapy. Consensus Statements encapsulating the implications of the material discussed with respect to the design of future clinical trials of LT4/LT3 combination therapy were generated. Authors voted upon the Consensus Statements. Iterative changes were made in several rounds of voting and after comments from ATA/BTA/ETA members. Results: Of 34 Consensus Statements available for voting, 28 received at least 75% agreement, with 13 receiving 100% agreement. Those with 100% agreement included studies being powered to study the effect of deiodinase and thyroid hormone transporter polymorphisms on study outcomes, inclusion of patients dissatisfied with their current therapy and requiring at least 1.2 μg/kg of LT4 daily, use of twice daily LT3 or preferably a slow-release preparation if available, use of patient-reported outcomes as a primary outcome (measured by a tool with both relevant content validity and responsiveness) and patient preference as a secondary outcome, and utilization of a randomized placebo-controlled adequately powered double-blinded parallel design. The remaining statements are presented as potential additional considerations. Discussion: This article summarizes the areas discussed and presents Consensus Statements to guide development of future clinical trials of LT4/LT3 combination therapy. The results of such redesigned trials are expected to be of benefit to patients and of value to inform future thyroid hormone replacement clinical practice guidelines treatment recommendations.

AB - Background: Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Methods: The American Thyroid Association (ATA), British Thyroid Association (BTA), and European Thyroid Association (ETA) held a joint conference on November 3, 2019 (live-streamed between Chicago and London) to review new basic science and clinical evidence regarding combination therapy with presentations and input from 12 content experts. After the presentations, the material was synthesized and used to develop Summary Statements of the current state of knowledge. After review and revision of the material and Summary Statements, there was agreement that there was equipoise for a new clinical trial of combination therapy. Consensus Statements encapsulating the implications of the material discussed with respect to the design of future clinical trials of LT4/LT3 combination therapy were generated. Authors voted upon the Consensus Statements. Iterative changes were made in several rounds of voting and after comments from ATA/BTA/ETA members. Results: Of 34 Consensus Statements available for voting, 28 received at least 75% agreement, with 13 receiving 100% agreement. Those with 100% agreement included studies being powered to study the effect of deiodinase and thyroid hormone transporter polymorphisms on study outcomes, inclusion of patients dissatisfied with their current therapy and requiring at least 1.2 μg/kg of LT4 daily, use of twice daily LT3 or preferably a slow-release preparation if available, use of patient-reported outcomes as a primary outcome (measured by a tool with both relevant content validity and responsiveness) and patient preference as a secondary outcome, and utilization of a randomized placebo-controlled adequately powered double-blinded parallel design. The remaining statements are presented as potential additional considerations. Discussion: This article summarizes the areas discussed and presents Consensus Statements to guide development of future clinical trials of LT4/LT3 combination therapy. The results of such redesigned trials are expected to be of benefit to patients and of value to inform future thyroid hormone replacement clinical practice guidelines treatment recommendations.

KW - Consensus

KW - Drug Combinations

KW - Evidence-Based Medicine

KW - Humans

KW - Hypothyroidism/blood

KW - Thyroxine/adverse effects

KW - Treatment Outcome

KW - Triiodothyronine/adverse effects

KW - clinical trial

KW - patient-reported outcomes

KW - hypothyroidism

KW - levothyroxine

KW - combination therapy

KW - liothyronine

UR - http://www.scopus.com/inward/record.url?scp=85100927999&partnerID=8YFLogxK

U2 - 10.1089/thy.2020.0720

DO - 10.1089/thy.2020.0720

M3 - Review

C2 - 33276704

AN - SCOPUS:85100927999

VL - 31

SP - 156

EP - 182

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 2

ER -

ID: 67033129